Current Size: 100%

Jorge Castillo, MD Presentations

Treatments Around the Corner for WM Jorge Castillo, MD – Dana Farber Cancer Institute, 2018 Ed Forum Discusses data from clinical trials for potential new treatments, such as ixazomib, dexamethasone, and rituximab as primary therapy, Venetoclax in previously treated WM, BTK inhibitor BGB-3111 in relapsed/refractory B-cell malignancies, Acalabrutinib (ACP-196), Ulocuplumab in CXCR4^WHIM patients with WM, and Daratumumab in previously treated patients with WM		Link to Castillo slides
Upfront Treatment Approaches Jorge Castillo, MD – Dana Farber Cancer Institute, IWWM9 Doctor-Patient Forum, 2016		Link to Castillo slides
Frontline Treatment Options for WM Jorge Castillo, MD - Dana-Farber Cancer Institute, 2016 Ed Forum Reviews the manifestations of WM disease, NCCN guidelines for initiation of treatment for WM, single agent treatments, combination therapies, maintenance, and new directions, including frontier clinical trials at Dana Farber Cancer Institute		Link to Castillo slides
Genomic-based Advances in WM On March 6, 2016, Dr. Jorge Castillo spoke to the Philadelphia IWMF Support Group on Genomic-based Advances in WM. Dr. Castillo, of the Dana-Farber Cancer Institute, is one of the world’s leading clinicians for Waldenstrom’s macroglobulinemia, and provides a valuable perspective, especially since: There are approximately 1,500 WM patients diagnosed each year in the United States. Dr. Castillo sees approximately 750 WM patients each year! Most community oncologists see 0, 1, 2, or 3 WM patients in their career, Dr. Castillo probably sees more WM patients in a morning than most oncologists see in a lifetime. This video is almost 2 hours in length.		No slides available

Section:

Google Adwords: